Literature DB >> 20008623

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.

Kelly A Metcalfe1, Aletta Poll, Robert Royer, Marcia Llacuachaqui, Anna Tulman, Ping Sun, Steven A Narod.   

Abstract

PURPOSE: There are two mutations in BRCA1 and one mutation in BRCA2 that are present in up to 2.5% of Ashkenazi Jewish women. Current guidelines for testing stipulate that a personal or family history of cancer be present to be eligible for testing. To date, population screening in this population has not been suggested. However, this may be rational. Little is known about the appropriateness of testing guidelines for the Jewish population or the level of interest in testing.
METHODS: Eligible subjects were women who self-identified as Jewish, who were between the ages of 25 and 80 years, and who resided in Ontario. Subjects were recruited through an article in a national newspaper. Women were asked to complete a study questionnaire and a family history questionnaire and to provide a blood or saliva sample. The risk of carrying a BRCA mutation was estimated for each woman. Results A total of 2,080 women were enrolled onto the study. The overall mutation prevalence was 1.1% (0.5% for BRCA1 and 0.6% for BRCA2). Among the 22 mutation carriers, the mean estimate of carrying a BRCA mutation was 3.9%. Ten (45%) of the 22 women met the current Ontario Ministry of Health Guidelines criteria for testing.
CONCLUSION: There is considerable interest for genetic testing among Jewish women at low risk of carrying a mutation. However, many women with mutations are ineligible for genetic testing under current guidelines. Approximately 1% of Jewish women carry a BRCA mutation, and these women should be considered to be candidates for genetic testing.

Entities:  

Mesh:

Year:  2009        PMID: 20008623     DOI: 10.1200/JCO.2009.25.0712

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  64 in total

1.  Personalized medicine: a personal view.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

2.  Re. Multimodality breast cancer screening in women with a familial or genetic predisposition.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2010-11       Impact factor: 3.677

Review 3.  Population genetic testing for cancer susceptibility: founder mutations to genomes.

Authors:  William D Foulkes; Bartha Maria Knoppers; Clare Turnbull
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

4.  Is it time to offer BRCA1 and BRCA2 testing to all Jewish women?

Authors:  K A Metcalfe; A Eisen; J Lerner-Ellis; S A Narod
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

5.  Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London.

Authors:  Kelly Kohut; Lucia D'Mello; Elizabeth K Bancroft; Sarah Thomas; Mary-Anne Young; Kathryn Myhill; Susan Shanley; Brian H J Briggs; Michelle Newman; Ifthikhar M Saraf; Penny Cox; Sarah Scambler; Lyndon Wagman; Michael T Wyndham; Rosalind A Eeles; Michelle Ferris
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

6.  Persistent Underutilization of BRCA1/2 Testing Suggest the Need for New Approaches to Genetic Testing Delivery.

Authors:  Anne Marie McCarthy
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

7.  To reflex or not: additional BRCA1/2 testing in Ashkenazi Jewish individuals without founder mutations.

Authors:  Nancie Petrucelli; Sarah Mange; Jennifer L Fulbright; Lindsay Dohany; Dana Zakalik; Debra Duquette
Journal:  J Genet Couns       Date:  2014-09-09       Impact factor: 2.537

8.  Use of BRCA Mutation Test in the U.S., 2004-2014.

Authors:  Fangjian Guo; Jacqueline M Hirth; Yu-Li Lin; Gwyn Richardson; Lyuba Levine; Abbey B Berenson; Yong-Fang Kuo
Journal:  Am J Prev Med       Date:  2017-03-22       Impact factor: 5.043

9.  Community attitudes towards a Jewish community BRCA1/2 testing program.

Authors:  Nicole Cousens; Rajneesh Kaur; Bettina Meiser; Lesley Andrews
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

10.  Integrating the Genetics of Race and Ethnicity Into Cancer Research: Trailing Jane and John Q. Public.

Authors:  Lisa A Newman; John Carpten
Journal:  JAMA Surg       Date:  2018-04-01       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.